NVIDIA 支持的 AI 制药公司 Iambic 递交纳斯达克 IPO 申请,生物科技上市回暖
Biotech IPOs Roar Back, With Nvidia-Backed Iambic Next in Line
总部位于圣地亚哥、2019 年由 Thomas Miller 与 Fred Manby 创立的 AI 制药公司 Iambic Therapeutics 已提交 S-1 文件,计划在纳斯达克上市,股票代码为 IAM,但尚未确定发行股数和价格区间。
Recently, Iambic Therapeutics has filed to go public on Nasdaq under the ticker IAM, adding another closely watched name to a biotech IPO market that has begun to reopen after one of its weakest years in recent memory.
The San Diego company, founded in 2019 by CEO Thomas Miller and CTO Fred Manby, disclosed its Form S-1 on Monday without setting a share count or price range. Iambic combines human-led drug discovery with AI-enabled computational methods. J.P. Morgan, Jefferies, BofA Securities and Citigroup are leading the offering.
According to the filing, the company’s top use of proceeds will be for their AI-designed IAM1363 for HER2-wild-type and HER2-mutated cancers, such as non-small cell lung cancer. The asset is an oral brain-penetrant HER2 inhibitor, and is now in phase 1 testing for advanced HER2-altered solid tumors, with a potential registrational study targeted for as early as 2027.

From Iambic pipeline
The filing comes as biotech issuance rebounds from an exceptionally weak 2025, when just 11 drug developers went public on U.S. exchanges, the lowest level since the pandemic. For comparison, according to BioSpace, 2024 had 19 companies completing their US IPOs, 2023—13, and 2022 had 17.
In these almost nine months of 2026, 26 biotechs had gone public, and several of the U.S. deals were substantially larger than the offerings seen during the downturn.
The year opened with Aktis Oncology’s $318 million Nasdaq debut, followed by Eikon Therapeutics’ $381 million offering, Veradermics' $256 million offering and Generate’ $400 million IPO in February. In the spring, Kailera Therapeutics priced a $625 million offering, eventually taking gross proceeds to $718.8 million after the underwriters exercised their option in full. Parabilis Medicines followed with a $670 million IPO in June, and Kardigan priced an upsized $400 million deal.
The reopening has extended beyond loud headline transactions—smaller rounds have been completed all across the globe.
To read the rest of this article, upgrade to a BiopharmaTrend Pro subscription.
Gain full access to all of our deep dives and content archives.
ADARx Pharmaceuticals Aktis Oncology Eikon Therapeutics Generate Biomedicines Iambic Therapeutics
来源:BiopharmaTrend · biopharmatrend.com